ASH 2019 | MRD as a marker in follicular lymphoma: importance and limitations
Alessandro Pulsoni
• 7 Dec 2019
Alessandro Pulsoni, MD, Sapienza University of Rome, Rome, Italy, discusses the importance of measurable residual disease (MRD) as a marker, its limitations and MRD evaluation methods. Prof. Pulsoni thinks MRD can be considered a reliable marker for treatment response in patients with follicular lymphoma. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
